End Stage Renal Disease (ESRD) Drug Market Trends Report 2025 – For Business Development and Strategy Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the End Stage Renal Disease (ESRD) Drug Market Growth in 2025?
The market for drugs treating end stage renal disease (ESRD) has experienced significant expansion lately. Forecasts predict its size to increase from $131.41 billion in 2024 to $149.88 billion in 2025, reflecting a compound annual growth rate (CAGR) of 14.1%. The historical growth can be attributed to a higher incidence of ESRD, a rising elderly population, better access to healthcare services, government actions and policies, as well as an uptick in the utilization of renal replacement therapies.
What Is the Forecast for the End Stage Renal Disease (ESRD) Drug Market Size Through 2029?
In the coming years, the market size for drugs treating end stage renal disease (ESRD) is projected to witness a swift expansion. The expected growth rate will peak at $268.44 billion in 2029 with a compound annual growth rate (CAGR) of 15.7%. The anticipated growth in this period can be related to the advent of innovative drugs and therapies, augmented healthcare spending, heightened global chronic kidney disease incidences, personalized treatment methods, supportive regulations, and accelerated approval processes. The key trends for this period consist of the rising prevalence of end stage renal disease, progress in treatment methods, a heightened focus on precision medicine, the inception of combination therapies, and the incorporation of technology in healthcare.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
What are the Key Market Players in End Stage Renal Disease (ESRD) Drug Market and How They’re Evolving?
Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA
What Are the Primary Growth Drivers in the End Stage Renal Disease (ESRD) Drug Market?
The escalating incidence of obesity and diabetes is projected to fuel the expansion of the end-stage renal disease (ESRD) drug market in the future. Obesity is characterized as unusually high or disproportionate accumulation of fat, presenting a risk to health. Conversely, diabetes is an enduring disease that occurs when either the pancreas fails to generate sufficient insulin or the body is unable to optimally use the insulin that is produced. The management of fluid and electrolyte levels, blood pressure, and the elimination of waste products through dialysis can enhance the overall health and comfort of patients with kidney diseases, possibly resulting in weight loss and better control of blood sugar. For instance, World Obesity, a US-based organization representing national and regional societies committed to obesity research and treatment, reported in March 2022 that the number of obese individuals is expected to escalate to 892 million by 2025 and further to 1,025 million by 2030. Moreover, as per the National Health Service, a publicly financed healthcare system based in the UK, by 2030, it is predicted that the count of people with diabetes in the UK could escalate to 5.5 million, implicating almost 9% of the population. Consequently, the increasing instances of obesity and diabetes are set to propel the market growth of end-stage renal disease (ESRD) drugs.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp
What Are the Leading Segments in the Global End Stage Renal Disease (ESRD) Drug Industry?
The end stage renal disease (ESRD) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
What Are the Key Market Trends in the End Stage Renal Disease (ESRD) Drug Industry?
In the end-stage renal disease (ESRD) drug market, a proactive focus on product developments is becoming a crucial strategy to gain traction. Leading entities in the ESRD drug sector are emphasizing inventive solutions to maintain their market standing. One such example is the announcement made in April 2022 by GlaxoSmithKline PLC, a pioneer in the pharmaceutical and biotech industry hailing from the UK. They revealed that the US Food and Drug Administration (FDA) has endorsed their New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), targeted to potentially assist patients battling chronic kidney disease anemia (CKD). This innovative product draws from the exclusive Nobel prize-winning scientific discovery elucidating how cells perceive and adjust to the level of available oxygen.
Access The Full Report Here:
What Is the Regional Outlook for the End Stage Renal Disease (ESRD) Drug Market?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9437
This Report Delivers Insight On:
1. How big is the end stage renal disease (esrd) drug market, and how is it changing globally?
2. Who are the major companies in the end stage renal disease (esrd) drug market, and how are they performing?
3. What are the key opportunities and risks in the end stage renal disease (esrd) drug market right now?
4. Which products or customer segments are growing the most in the end stage renal disease (esrd) drug market?
5. What factors are helping or slowing down the growth of the end stage renal disease (esrd) drug market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
